Dynamics of CD81 expression on lymphocyte subsets during interferon-α-based antiviral treatment of patients with chronic hepatitis C

Journal of Leukocyte Biology

Temam Ghaliai²  Stefan Zeuzem²  Ulrike Mihm²  W. Peter Hofmann²  Christoph Sarrazin²  Martina Sester¹  Heiner Wedemeyer³  Bernd Kronenberger²  Eva Herrmann² 

[1] IV, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany; and IV, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany; and IV, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany; and;Klinik für Innere Medizin II and Klinik für Innere Medizin II and Klinik für Innere Medizin II and;Medizinische Hochschule Hannover, Germany Medizinische Hochschule Hannover, Germany Medizinische Hochschule Hannover, Germany

关键词: host-cell interaction;    antiviral immune response;   

DOI  :  10.1189/jlb.0106047

学科分类：生理学

来源: Federation of American Societies for Experimental Biology

【 摘 要 】

CD81 is a hepatitis C virus (HCV) coreceptor with important functions in lymphocytes. During treatment, CD81 expression may be changed directly by the antiviral therapy or indirectly by reduction of the HCV serum level. The regulation of CD81 on lymphocyte subtypes has not been investigated so far and may be relevant for the control of viral infection and treatment response. CD81 was analyzed by flow cytometry in CD8(+), CD4(+), CD19(+), and CD56(+) lymphocyte subtypes from 20 patients with chronic hepatitis C before, during, and after antiviral treatment with pegylated interferon-α (IFN-α) and ribavirin. A sustained virologic response (SVR) was achieved in 11 patients. Dynamics of CD81 were investigated in correlation with HCV-RNA dynamics and the outcome of therapy. During treatment, the following typical patterns of CD81 regulation were observed: down-regulation on CD8(+) T cells (P=0.022) and most significantly, on CD56(+) natural killer cells (P<0.001), transient up-regulation on CD19(+) B cells (P=0.006), and weak and late down-regulation on CD4(+) T cells (P=0.028). During treatment, CD81 expression was not associated with the HCV-RNA serum level on all lymphocyte subtypes. After end of treatment, CD81 increased again in CD8(+) and CD56(+) cells (P=0.001, P=0.002). On CD8(+) T cells post-treatment, CD81 remained lower in patients who achieved a SVR compared with patients who failed to eliminate HCV after treatment (P=0.033). Lymphocyte subsets show different patterns of CD81 response before and during antiviral treatment, which are associated with administration of IFN-α and antiviral response.

【 授权许可】

Unknown